Distinct immunotherapy immune response phenotypes in non-small cell lung cancer present with unique genomic alteration profiles

Distinct genomic alterations were identified in different gene expression and immunotherapy marker defined immune-response phenotypes, with tumor-dominant phenotype tumors having the highest number of enriched alterations. These genomic alterations, along with gene expression and immunotherapy marker characteristics of each phenotype, shed light on the mechanisms behind varying responses to immunotherapy in NSCLC.